HALIFAX, Jan. 5 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that Stephen Sham is retiring as the Chairman of
the Board of Directors. Mr. Sham will step down as Chairman and will not seek
re-election to the Board of Directors in the coming term.
"I have decided that the time is right for me to retire," said Stephen
Sham. "I have completed my role here and I am leaving MedMira in good hands
and wish the Company well in its future progress."
"On behalf of everyone at the Company and our Board of Directors I want
to thank Stephen for his contributions to MedMira. We are very appreciative of
his support and guidance through the years he served as both CEO and Chairman
of the Board," said Hermes Chan, president and CEO, MedMira Inc. "Stephen's
contributions to MedMira in the past 15 years have played a key role in
helping us move forward from a start-up to become an internationally
recognized company in the diagnostics industry, and we wish him well in his
The Company expects to name a successor at its next board meeting after
the Annual General Meeting.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: MedMira Contact: Andrea Young, Corporate
Communications, (902) 450-1588, firstname.lastname@example.org; Dr. James Smith, Investor
Relations & Corporate Affairs, (902) 450-1588, email@example.com